Amedisys (AMED) Competitors $93.56 -0.03 (-0.03%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$93.54 -0.02 (-0.02%) As of 07:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMED vs. DVA, CHE, CRVL, MD, AMN, CCRN, LH, DGX, OPCH, and BTSGShould you be buying Amedisys stock or one of its competitors? The main competitors of Amedisys include DaVita (DVA), Chemed (CHE), CorVel (CRVL), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), Laboratory Co. of America (LH), Quest Diagnostics (DGX), Option Care Health (OPCH), and BrightSpring Health Services (BTSG). Amedisys vs. DaVita Chemed CorVel Pediatrix Medical Group AMN Healthcare Services Cross Country Healthcare Laboratory Co. of America Quest Diagnostics Option Care Health BrightSpring Health Services Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, community ranking, risk and analyst recommendations. Is AMED or DVA more profitable? DaVita has a net margin of 7.31% compared to Amedisys' net margin of 3.57%. DaVita's return on equity of 115.48% beat Amedisys' return on equity.Company Net Margins Return on Equity Return on Assets Amedisys3.57% 12.20% 6.74% DaVita 7.31%115.48%4.94% Which has more risk and volatility, AMED or DVA? Amedisys has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Which has higher earnings and valuation, AMED or DVA? DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmedisys$2.37B1.29-$9.75M$2.7134.52DaVita$12.97B0.81$936.34M$10.0913.73 Does the MarketBeat Community believe in AMED or DVA? DaVita received 2 more outperform votes than Amedisys when rated by MarketBeat users. Likewise, 61.10% of users gave DaVita an outperform vote while only 58.63% of users gave Amedisys an outperform vote. CompanyUnderperformOutperformAmedisysOutperform Votes49658.63% Underperform Votes35041.37% DaVitaOutperform Votes49861.10% Underperform Votes31738.90% Do analysts prefer AMED or DVA? Amedisys presently has a consensus price target of $100.75, indicating a potential upside of 7.68%. DaVita has a consensus price target of $164.50, indicating a potential upside of 18.73%. Given DaVita's higher probable upside, analysts clearly believe DaVita is more favorable than Amedisys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amedisys 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20DaVita 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to AMED or DVA? In the previous week, DaVita had 18 more articles in the media than Amedisys. MarketBeat recorded 24 mentions for DaVita and 6 mentions for Amedisys. Amedisys' average media sentiment score of 1.67 beat DaVita's score of 1.12 indicating that Amedisys is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amedisys 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DaVita 15 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in AMED or DVA? 94.4% of Amedisys shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 2.1% of Amedisys shares are held by insiders. Comparatively, 2.0% of DaVita shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryDaVita beats Amedisys on 10 of the 17 factors compared between the two stocks. Get Amedisys News Delivered to You Automatically Sign up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMED vs. The Competition Export to ExcelMetricAmedisysHome health care services IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.07B$3.16B$5.33B$8.39BDividend YieldN/A0.34%5.21%4.11%P/E Ratio37.1329.4826.7119.71Price / Sales1.291.13386.47120.65Price / Cash14.8017.2938.2534.62Price / Book2.733.596.774.50Net Income-$9.75M-$57.02M$3.23B$248.22M7 Day Performance-1.12%-3.66%0.48%-0.78%1 Month Performance-0.02%15.03%9.10%11.53%1 Year Performance-2.74%26.93%18.56%8.99% Amedisys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMEDAmedisys2.6801 of 5 stars$93.560.0%$100.75+7.7%-3.3%$3.07B$2.37B37.1320,000Positive NewsDVADaVita3.9979 of 5 stars$144.29+0.4%$166.33+15.3%+2.8%$11.09B$12.82B13.4370,000Positive NewsCHEChemed4.7068 of 5 stars$569.50-0.1%$674.00+18.3%+0.6%$8.33B$2.49B28.7814,200Positive NewsDividend AnnouncementCRVLCorVel1.0099 of 5 stars$114.08+1.4%N/A+22.7%$5.86B$871.31M67.114,230News CoveragePositive NewsEarnings ReportUpcoming EarningsMDPediatrix Medical Group1.3332 of 5 stars$14.34-1.3%$16.67+16.2%+85.6%$1.23B$1.98B-11.957,850Positive NewsAMNAMN Healthcare Services4.5295 of 5 stars$22.67+3.0%$38.67+70.6%-62.0%$865.75M$2.85B-5.894,230Positive NewsCCRNCross Country Healthcare3.8995 of 5 stars$13.92-0.6%$18.41+32.2%-7.1%$456.34M$1.26B-278.342,700Positive NewsLHLaboratory Co. of America4.7403 of 5 stars$250.89+2.1%$270.62+7.9%+20.2%$21.00B$13.18B28.4575,500Positive NewsDGXQuest Diagnostics4.8424 of 5 stars$175.93-0.6%$185.73+5.6%+19.5%$19.64B$10.16B22.8849,000News CoveragePositive NewsAnalyst RevisionOPCHOption Care Health4.2133 of 5 stars$31.86+0.1%$35.50+11.4%+10.3%$5.22B$5.19B26.775,600Positive NewsBTSGBrightSpring Health Services1.6286 of 5 stars$22.35-2.1%$22.89+2.4%+99.7%$3.89B$11.86B-85.9635,000Positive NewsHigh Trading Volume Related Companies and Tools Related Companies DVA Competitors CHE Competitors CRVL Competitors MD Competitors AMN Competitors CCRN Competitors LH Competitors DGX Competitors OPCH Competitors BTSG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMED) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amedisys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.